36.52
price down icon1.62%   -0.60
after-market Handel nachbörslich: 36.54 0.02 +0.05%
loading
Schlusskurs vom Vortag:
$37.12
Offen:
$37.49
24-Stunden-Volumen:
2.65M
Relative Volume:
2.75
Marktkapitalisierung:
$3.55B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-5.6445
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-1.67%
1M Leistung:
+4.10%
6M Leistung:
-15.89%
1J Leistung:
-11.83%
1-Tages-Spanne:
Value
$35.59
$38.19
1-Wochen-Bereich:
Value
$35.59
$38.19
52-Wochen-Spanne:
Value
$29.59
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Firmenname
Ultragenyx Pharmaceutical Inc
Name
Telefon
415-483-8800
Name
Adresse
60 LEVERONI COURT, NOVATO, CA
Name
Mitarbeiter
1,294
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
RARE's Discussions on Twitter

Vergleichen Sie RARE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
36.52 3.55B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-28 Eingeleitet William Blair Outperform
2024-06-06 Hochstufung Goldman Neutral → Buy
2024-04-22 Eingeleitet RBC Capital Mkts Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-06-06 Hochstufung Evercore ISI In-line → Outperform
2023-04-26 Eingeleitet Cantor Fitzgerald Overweight
2023-01-18 Fortgesetzt Canaccord Genuity Buy
2022-12-30 Fortgesetzt H.C. Wainwright Buy
2022-11-03 Hochstufung Robert W. Baird Neutral → Outperform
2022-10-13 Hochstufung Guggenheim Neutral → Buy
2022-08-01 Herabstufung Evercore ISI Outperform → In-line
2022-03-16 Hochstufung Credit Suisse Neutral → Outperform
2022-02-11 Hochstufung JP Morgan Neutral → Overweight
2021-09-30 Eingeleitet H.C. Wainwright Buy
2021-08-19 Eingeleitet UBS Sell
2021-07-15 Eingeleitet Guggenheim Neutral
2021-06-29 Hochstufung BofA Securities Neutral → Buy
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-05-06 Hochstufung Citigroup Neutral → Buy
2021-05-06 Hochstufung Evercore ISI In-line → Outperform
2021-04-26 Fortgesetzt Credit Suisse Neutral
2021-03-02 Fortgesetzt Stifel Buy
2021-02-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-07 Herabstufung Wedbush Outperform → Neutral
2020-11-24 Fortgesetzt Evercore ISI In-line
2020-11-12 Herabstufung BofA Securities Buy → Neutral
2019-08-02 Fortgesetzt Wedbush Outperform
2019-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-02-22 Fortgesetzt Raymond James Outperform
2019-01-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-11-08 Hochstufung Citigroup Sell → Neutral
2018-09-10 Eingeleitet Morgan Stanley Equal-Weight
2018-06-21 Herabstufung Credit Suisse Outperform → Neutral
2018-05-11 Hochstufung Barclays Equal Weight → Overweight
2018-05-10 Eingeleitet Goldman Neutral
2018-04-18 Hochstufung SunTrust Hold → Buy
2018-03-22 Fortgesetzt Piper Jaffray Overweight
2018-02-21 Bestätigt Stifel Buy
2018-01-22 Hochstufung Evercore ISI In-line → Outperform
2018-01-18 Eingeleitet Credit Suisse Outperform
2017-12-05 Bestätigt Barclays Equal Weight
2017-12-04 Hochstufung Jefferies Hold → Buy
2017-09-14 Hochstufung Wedbush Neutral → Outperform
Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Jun 18, 2025

Exploring the Road Ahead: X-linked Hypophosphatemia Market - openPR.com

Jun 18, 2025
pulisher
Jun 16, 2025

(RARE) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 14, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com Canada

Jun 14, 2025
pulisher
Jun 14, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

FDA approves Ultragenyx's Mepsevii in mucopolysaccharidosis type VII enzyme disorder - FirstWord Pharma

Jun 13, 2025
pulisher
Jun 10, 2025

Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener

Jun 10, 2025
pulisher
Jun 09, 2025

Ultragenyx (RARE) Q1 2025 Performance Shows Resilience - GuruFocus

Jun 09, 2025
pulisher
Jun 05, 2025

Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat

Jun 05, 2025
pulisher
Jun 05, 2025

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan

Jun 03, 2025
pulisher
May 29, 2025

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com

May 29, 2025
pulisher
May 29, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World

May 29, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga

May 28, 2025
pulisher
May 28, 2025

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com

May 28, 2025
pulisher
May 28, 2025

Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria

May 25, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com

May 25, 2025
pulisher
May 21, 2025

CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com

May 21, 2025
pulisher
May 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 21, 2025
pulisher
May 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN

May 20, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com

May 12, 2025

Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):